House Publications

The Debates are the report—transcribed, edited, and corrected—of what is said in the House. The Journals are the official record of the decisions and other transactions of the House. The Order Paper and Notice Paper contains the listing of all items that may be brought forward on a particular sitting day, and notices for upcoming items.

For an advanced search, use Publication Search tool.

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

Previous day publication Next day publication

Bilingual view PDF


Wednesday, February 9, 2011 (No. 127)

Report Stage of Bills

Bill C-20

An Act to amend the National Capital Act and other Acts

Notices of Motions

Motion No. 1 — November 16, 2010 — — That Bill C-20, in Clause 10, be amended by replacing line 7 on page 6 with the following:

“Commission shall consult the provinces concerned and provide opportunities for”

Motion No. 2 — November 16, 2010 — — That Bill C-20, in Clause 10, be amended by replacing line 31 on page 7 with the following:

“as its priority the maintenance or”


Bill C-393
An Act to amend the Patent Act (drugs for international humanitarian purposes) and to make a consequential amendment to another Act
Pursuant to Standing Order 76.1(5), the Speaker selected and grouped for debate the following motions:
Group No. 1 -- Motions Nos. 1 to 3.
Statement and selection by Speaker — see Debates of January 31, 2011.

Resuming Debate

Group No. 1

Amendment to Motion No. 1 -- Question put separately.

Motion No. 1 -- Question put separately.

Amendment to Motion No. 2 -- Question put separately.

Motion No. 2 -- Question put separately.

Motion No. 3 -- Question put only if Motion No. 2 is agreed.

Motion No. 1 — January 31, 2011 — , seconded by , — That Bill C-393 be amended by restoring Clause 2 as follows:

“2. Section 21.02 of the Act is replaced by the following:

21.02 The definitions in this section apply in sections 21.01 to 21.16.

“authorization” means an authorization granted under subsection 21.04(1).

“pharmaceutical product” means any drug, as defined in section 2 of the Food and Drugs Act, and includes monitoring products and products used in conjunction with a pharmaceutical product.”

Amendment to Motion No. 1 — January 31, 2011 — , seconded by , — That the motion proposing to restore Clause 2 of Bill C-393 be amended by replacing the definition “pharmaceutical product” with the following:

““pharmaceutical product” means any patented product listed in Schedule 1 in, if applicable, the dosage form, the strength and the route of administration specified in that Schedule in relation to the product and any other patented product, or product manufactured through a patented process, of the pharmaceutical sector needed to address public health problems, especially those resulting from HIV/AIDS, tuberculosis, malaria and other epidemics, and includes active ingredients necessary for its manufacture and diagnostic kits needed for its use.”.

Motion No. 2 — January 31, 2011 — , seconded by , — That Bill C-393 be amended by restoring Clause 4 as follows:

“4. (1) Subsection 21.04(1) of the Act is replaced by the following:

21.04 (1) Subject to subsections (3) and (4), the Commissioner shall, on the application of any person and on the payment of the prescribed fee, authorize the person to

(a) manufacture the pharmaceutical product or products named in the application;

(b) make, construct and use any patented invention solely for the purpose of manufacturing the product or products; and

(1.1) In addition to what is authorized under subsection (1), an authorization under that subsection authorizes the person to

(a) manufacture any active ingredient used in the manufacture of a finished product; and

(b) make, construct and use any patented invention solely for the purpose of manufacturing any active pharmaceutical ingredient used in the manufacture of a finished product.

(1.2) If a country is removed from the Schedule an authorization continues to apply with respect to that country for 30 days as though that country had not been removed from the Schedule.

(2) Subsection 21.04(2) of the Act is amended by adding “and” at the end of paragraph (a) and by repealing paragraphs (b) to (f).

(3) Subsection 21.04(3) of the Act is replaced by the following:

(3) The Commissioner shall grant an authorization only if the applicant has complied with the prescribed requirements.”

Amendment to Motion No. 2 — January 31, 2011 — , seconded by , — That the Motion proposing to restore Clause 4 of Bill C-393 be amended by deleting all the words after the words “4. (1)Subsection 21.04(1) of the Act is replaced by the following:” and substituting the following:

“21.04 (1) Subject to subsection (3), the Commissioner shall, on the application of any person and on the payment of the prescribed fee, authorize the person to make, construct and use a patented invention solely for purposes directly related to the manufacture of the pharmaceutical product named in the application and to sell it for export to any country listed in Schedule 2.

(2) Paragraph 21.04(2)(c) of the Act is repealed.

(3) Paragraphs 21.04(2)(e) and (f) of the Act are repealed.

(4) Subparagraphs 21.04(3)(c)(i) and (ii) of the Act are replaced by the following:

(i) sought from the patentee or, if there is more than one, from each of the patentees, by certified or registered mail, a licence to manufacture and sell the pharmaceutical product for export to one or more of the countries listed in Schedule 2 on reasonable terms and conditions and that such efforts have not been successful; and

(ii) provided the patentee, or each of the patentees, as the case may be, by certified or registered mail, in the written request for a licence, with the information that is in all material respects identical to the information referred to in subsection (2).

(5) Paragraph 21.04(3)(d) of the Act is repealed.

(6) Section 21.04 is amended by adding the following after subsection (3):

“(4) The solemn or statutory declaration referred to in paragraph (3)(c) is not required in the case of an application to the Commissioner for an authorization to supply the product named in the application to an eligible importing country for purposes of addressing a national emergency or other circumstances of extreme urgency in that country or for purposes of public non-commercial use, but in such cases, the Commissioner shall notify the patentee or patentees of the issuance of the compulsory licence as soon as reasonably practicable after it has been issued.””.

Motion No. 3 — January 31, 2011 — , seconded by , — That Bill C-393 be amended by adding after line 22 on page 3 the following new clause:

“18. (1) The provisions of this Act that amend the Patent Act shall cease to apply on the day that is the fourth anniversary of the day on which this Act comes into force unless, before that day, the application of those provisions is extended by a resolution — the text of which is established under subsection (2) — passed by both Houses of Parliament in accordance with the rules set out in subsection (3).

(2) The Governor in Council may, by order, establish the text of a resolution providing for the extension of the application of the provisions that amend the Patent Act referred to in subsection (1) and specifying the period of the extension, which may not exceed five years from the first day on which the resolution has been passed by both Houses of Parliament.

(3) A motion for the adoption of the resolution may be debated in both Houses of Parliament but may not be amended. At the conclusion of the debate, the Speaker of each House of Parliament shall immediately put every question necessary to determine whether or not the motion is concurred in.

(4) The application of the provisions that amend the Patent Act referred to in subsection (1) may be further extended in accordance with the procedure set out in this section.

(5) In the event that the provisions that amend the Patent Act referred to in subsection (1) cease to apply, applications that have been granted an authorization under section 21.04 of that Act shall be concluded if they were submitted before the day on which those provisions cease to apply.”


Bill C-474
An Act respecting the Seeds Regulations (analysis of potential harm)
Pursuant to Standing Order 76.1(5), the Speaker selected and grouped for debate the following motions:
Group No. 1 -- Motions Nos. 1 to 10.
Statement and selection by Speaker — see Debates of December 1, 2010.

Deferred Recorded Divisions

Group No. 1

Motion No. 1 -- Question put separately.

Motion No. 2 -- Question put separately.

Motion No. 3 -- Question put separately.

Motion No. 4 -- Question put separately.

Motion No. 5 -- Question put separately.

Motion No. 6 -- Question put separately.

Motion No. 7 -- Question put separately.

Motion No. 8 -- Question put separately.

Motion No. 9 -- Question put separately.

Motion No. 10 -- Question put separately.

Motion No. 1 — February 8, 2011 — Deferred recorded division on the motion of , seconded by , — That Bill C-474, in Clause 2, be amended by replacing line 6 on page 1 with the following:

“2. The Governor in Council shall, within 90”

Motion No. 2 — February 8, 2011 — Deferred recorded division on the motion of , seconded by , — That Bill C-474, in Clause 2, be amended by replacing line 10 on page 1 with the following:

“by the Government of Canada, published in the Canada Gazette and taken into consideration by the Government of Canada before the sale of any new genetically en-”

Motion No. 3 — February 8, 2011 — Deferred recorded division on the motion of , seconded by , — That Bill C-474, in Clause 2, be amended by replacing line 11 on page 1 with the following:

“gineered seed is permitted in Canada.”

Motion No. 4 — February 8, 2011 — Deferred recorded division on the motion of , seconded by , — That Bill C-474 be amended by adding after line 11 on page 1 the following new clause:

“3. The results of the analysis referred to in section 2 shall be included as part of every application that is made for the registration of a variety of seed and any notification of the release of the seed in question into the environment.”

Motion No. 5 — February 8, 2011 — Deferred recorded division on the motion of , seconded by , — That Bill C-474 be amended by adding after line 11 on page 1 the following new clause:

“3. The analysis referred to in section 2 shall take into account the regulatory systems that govern genetically engineered seed and the crops and products that are derived from that seed in the countries that import Canadian agricultural products.”

Motion No. 6 — February 8, 2011 — Deferred recorded division on the motion of , seconded by , — That Bill C-474 be amended by adding after line 11 on page 1 the following new clause:

“3. The analysis referred to in section 2 shall take into account the economic impact on Canadian farmers and exporters whose established markets for registered seed or for the crops and products derived from that seed would be harmed as a result of the introduction of the new variety of genetically engineered seed.”

Motion No. 7 — February 8, 2011 — Deferred recorded division on the motion of , seconded by , — That Bill C-474 be amended by adding after line 11 on page 1 the following new clause:

“3. The analysis referred to in section 2 shall take into account whether or not the variety of genetically engineered seed in question has been approved for use in the countries that import Canadian agricultural products.”

Motion No. 8 — February 8, 2011 — Deferred recorded division on the motion of , seconded by , — That Bill C-474 be amended by adding after line 11 on page 1 the following new clause:

“3. In this Act, “genetically engineered seed” means a seed that has been altered using recombinant DNA (rDNA) technology.”

Motion No. 9 — February 8, 2011 — Deferred recorded division on the motion of , seconded by , — That Bill C-474 be amended by adding after line 11 on page 1 the following new clause:

“3. In this Act, “new”, in respect of a genetically engineered seed, means a genetically engineered seed that was not registered in Canada before the day on which this Act comes into force.”

Motion No. 10 — February 8, 2011 — Deferred recorded division on the motion of , seconded by , — That Bill C-474 be amended by adding after line 11 on page 1 the following new clause:

“3. For the purposes of section 2, “potential harm to export markets” exists if the sale of new genetically engineered seed in Canada would likely result in an economic loss to farmers and exporters as a result of the refusal, by one or more countries that import Canadian agricultural products, to allow the admission of any registered Canadian seed, or crops or products derived from that seed.”